Coronavirus Disease 2019-related dyspnea cases difficult to interpret using chest computed tomography

Abstract

Patients with Coronavirus Disease 2019 (COVID-19) often have clinical characteristics, such as chest tightness and dyspnea. Continuous, unresolved dyspnea often indicates the progression of lung lesions. The mechanism that underlies the chest distress and dyspnea in patients with COVID-19 is still unclear. Chest CT has a higher sensitivity and can play an essential role in the diagnosis and treatment of the disease. However, our clinical observations showed that although some patients had significant chest distress and dyspnea, the lesions that were observed in the lungs during computed tomography were milder and not completely consistent with clinical symptoms. We analyzed the clinical characteristics, laboratory test results, and imaging findings of these patients. We found that extensive inflammation of the bilateral and respiratory bronchioles in patients with COVID-19 due to excessive activation of proinflammatory cytokines and chemotactic aggregation of T-lymphocytes at the site of inflammation are possible mechanisms underlying chest distress and dyspnea in patients with COVID-19. Short-time and lose-dose use of corticosteroid may be helpful to treat chest tightness and dyspnea in mild COVID-19 patients. Through this study, we aimed to improve our understanding of the pathogenesis of COVID-19.

Airway Hygiene in COVID-19 Pneumonia: Treatment Responses of 3 Critically Ill Cruise Ship Employees

“…During the immediate exudative stage, diffuse alveolar damage (DAD) clinically manifests in progressive respiratory failure. In a study that analyzed chest computed tomography (CT) images of patients infected with COVID-19, thickened bronchial walls and distended bronchi indicated marked inflammatory infiltration within the lungs [ 24 ]. In agreement with this observation, an autopsy report of a patient with COVID-19 described lymphocytic infiltration and mucosal edema within bronchi and bronchioles [ 25 ].…”

K18-hACE2 mice develop respiratory disease resembling severe COVID-19

“…Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in Hubai province in mainland China in December 2019, and is the etiological agent of coronavirus disease (COVID)-19 ( 1 ). SARS-CoV-2 can cause asymptomatic to severe lower respiratory tract infections in humans, with early clinical signs including fever, cough and dyspnea ( 2 , 3 ). Progression to severe disease may be marked by acute respiratory distress syndrome (ARDS), with pulmonary edema, bilateral diffuse alveolar damage and hyaline membrane formation ( 4 – 6 ).…”

SARS-CoV-2 disease severity and transmission efficiency is increased for airborne but not fomite exposure in Syrian hamsters

“…Since the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Wuhan, China, in December 2019, the virus has spread across the globe and has caused over 70 million cases and 1.5 million deaths as of December 2020 [1]. Infection with SARS-CoV-2 can cause asymptomatic to severe lower respiratory tract infections in humans [2,3]. Peak respiratory shedding in humans occurs at the time of symptom onset or in the week thereafter, followed by a steady decline after the induction of a humoral immune response [4].…”